![Magnetic resonance imaging (MRI) of the brain, brain tumor](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/05/Press-Release-New-Trials-2000x600.jpg)
AZD1390 FOR GRADE 4 GLIOMA
About The Grade 4 Glioma
clinical trial
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1b clinical trial to evaluate AZD1390 in patients with recurrent and newly diagnosed WHO grade 4 glioma.
The goal of Phase 0 is to confirm that AZD1390 is capable of crossing the blood-brain barrier. Patients with positive results may advance to the 1b expansion phase which combines therapeutic dosing of AZD1390 with standard-of-care fractionated radiotherapy.
The expansion phase will examine progression-free survival and monitor safety and tolerability of AZD1390 in combination with radiation.
- AZD1390 is a highly potent brain penetrant ATM (Ataxia telangiectasia mutant) kinase inhibitor that blocks the repair of DNA breaks caused by radiation treatment.
- AZD1390 is in early clinical development for use as a radiosensitizer in central nervous system malignancies.
- Radiosensitizers make tumor cells more vulnerable to radiation therapy.
Grade 4 Glioma Trial Details
Recruiting
AZD1390
Recurrent and Newly Diagnosed WHO Grade 4 Glioma
47 Participants
![](https://www.ivybraintumorcenter.org/wp-content/uploads/2021/09/SanaiPatient_hexagon-1024x1022.png)
You may be eligible if:
- You are 18 years or older.
- You have a suspected newly diagnosed WHO grade 4 glioma and plain to follow the standard treatment regimen.
-OR-
- You are 18 years or older
- You have had prior resection (surgical removal) of a diagnosed WHO grade 4 glioma and followed standard therapy, including temozolomide and fractionated radiotherapy.
- Your doctor has told you that your tumor has recurred (come back) or has progressed (grown or changed) and you require resection with radiation therapy as part of your post-surgical treatment plan.
View all eligibility criteria by visiting ClinicalTrials.gov or call 602-406-8605 to speak with a patient navigator.
Phase 0 Clinical Trial: How it works
![Icon of Brain Tumor Patient](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_1@4x-257x300.png)
Once enrolled, a patient receives a short exposure to the experimental therapy days before a planned operation to remove their tumor.
![Glioblastoma Tumor Illustration](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_2@4x-300x300.png)
This exposure is enough that when we remove the tumor, our team of experts can answer an important question: Did the treatment penetrate the tumor?
![Combination Therapy for Gliboblastoma](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_3@4x-300x300.png)
If the drug penetrates the tumor at sufficient levels, the patient may move forward with receiving the treatment in combination with fractionated radiotherapy in the therapeutic expansion phase.
![Stopwatch Timer](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_4@4x-300x300.png)
Alternatively, if the treatment has no effect on the tumor, the patient can enroll in another clinical trial without losing time or receiving ineffective treatment.
Am I Eligible?
Submit a free trial screening request today to learn if you may qualify for a clinical trial or talk to an Ivy Navigator by calling 602-406-8605.